Cell Source OTC Stock Insiders
| CLCS Stock | USD 0.50 0.02 4.17% |
Cell Source employs about 1 people. The company is managed by 2 executives with a total tenure of roughly 10 years, averaging almost 5.0 years of service per executive, having 0.5 employees per reported executive. Breaking down Cell Source's management performance can provide insight into the firm performance.
| Itamar Shimrat CEO CEO and President CFO, Principal Accounting Officer and Director |
Cell |
Cell Source Management Team Effectiveness
The company has return on total asset (ROA) of (3.7761) % which means that it has lost $3.7761 on every $100 spent on assets. This is way below average. Cell Source's management efficiency ratios could be used to measure how well Cell Source manages its routine affairs as well as how well it operates its assets and liabilities.Cell Source Workforce Comparison
Cell Source is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 578. Cell Source adds roughly 1.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Cell Source Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cell Source Price Series Summation is a cross summation of Cell Source price series and its benchmark/peer.
Cell Source Notable Stakeholders
A Cell Source stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cell Source often face trade-offs trying to please all of them. Cell Source's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cell Source's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Itamar Shimrat | CEO and President CFO, Principal Accounting Officer and Director | Profile | |
| BSc MA | Ex Chairman | Profile |
About Cell Source Management Performance
The success or failure of an entity such as Cell Source often depends on how effective the management is. Cell Source management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
The data published in Cell Source's official financial statements typically reflect Cell Source's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Cell Source's quantitative information. For example, before you start analyzing numbers published by Cell accountants, it's essential to understand Cell Source's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the imprecision that can be found in Cell Source's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cell Source. Check Cell Source's Beneish M Score to see the likelihood of Cell Source's management manipulating its earnings.
Cell Source Workforce Analysis
Traditionally, organizations such as Cell Source use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cell Source within its industry.Cell Source Manpower Efficiency
Return on Cell Source Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.5M | |
| Net Loss Per Executive | 2.7M |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.